Mostrar el registro sencillo del ítem
dc.contributor.author | Bermejo-Martin, Jesús F | |
dc.contributor.author | García-Mateo, Nadia | |
dc.contributor.author | Motos, Anna | |
dc.contributor.author | Resino, Salvador | |
dc.contributor.author | Tamayo, Luis | |
dc.contributor.author | Ryan Murua, Pablo | |
dc.contributor.author | Bustamante-Munguira, Elena | |
dc.contributor.author | Gallego Curto, Elena | |
dc.contributor.author | Úbeda-Iglesias, Alejandro | |
dc.contributor.author | de la Torre, María Del Carmen | |
dc.contributor.author | Estella, Ángel | |
dc.contributor.author | Campos-Fernández, Sandra | |
dc.contributor.author | Martínez Varela, Ignacio | |
dc.contributor.author | Pérez-García, Felipe | |
dc.contributor.author | Socias, Lorenzo | |
dc.contributor.author | López Messa, Juan | |
dc.contributor.author | Vidal-Cortés, Pablo | |
dc.contributor.author | Sagredo Meneses, Víctor | |
dc.contributor.author | González-Rivera, Milagros | |
dc.contributor.author | Carbonell, Nieves | |
dc.contributor.author | de Gonzalo-Calvo, David | |
dc.contributor.author | Martín Delgado, María Cruz | |
dc.contributor.author | Valdivia, Luis Jorge | |
dc.contributor.author | Martín-López, Caridad | |
dc.contributor.author | Jorge García, Ruth Noemí | |
dc.contributor.author | Maseda, Emilio | |
dc.contributor.author | Loza-Vázquez, Ana | |
dc.contributor.author | Kelvin, David J | |
dc.contributor.author | Barbé, Ferrán | |
dc.contributor.author | Torres, Antoni | |
dc.contributor.author | CIBERES-UCI-COVID Group | |
dc.contributor.author | Martinez, Isidoro | |
dc.date.accessioned | 2023-05-11T12:17:20Z | |
dc.date.available | 2023-05-11T12:17:20Z | |
dc.date.issued | 2023-04-25 | |
dc.identifier.citation | Lancet Microbe. 2023 Jun;4(6):e431-e441. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/16054 | |
dc.description.abstract | Background: The contribution of the virus to the pathogenesis of severe COVID-19 is still unclear. We aimed to evaluate associations between viral RNA load in plasma and host response, complications, and deaths in critically ill patients with COVID-19. Methods: We did a prospective cohort study across 23 hospitals in Spain. We included patients aged 18 years or older with laboratory-confirmed SARS-CoV-2 infection who were admitted to an intensive care unit between March 16, 2020, and Feb 27, 2021. RNA of the SARS-CoV-2 nucleocapsid region 1 (N1) was quantified in plasma samples collected from patients in the first 48 h following admission, using digital PCR. Patients were grouped on the basis of N1 quantity: VIR-N1-Zero (<1 N1 copies per mL), VIR-N1-Low (1-2747 N1 copies per mL), and VIR-N1-Storm (>2747 N1 copies per mL). The primary outcome was all-cause death within 90 days after admission. We evaluated odds ratios (ORs) for the primary outcome between groups using a logistic regression analysis. Findings: 1068 patients met the inclusion criteria, of whom 117 had insufficient plasma samples and 115 had key information missing. 836 patients were included in the analysis, of whom 403 (48%) were in the VIR-N1-Low group, 283 (34%) were in the VIR-N1-Storm group, and 150 (18%) were in the VIR-N1-Zero group. Overall, patients in the VIR-N1-Storm group had the most severe disease: 266 (94%) of 283 patients received invasive mechanical ventilation (IMV), 116 (41%) developed acute kidney injury, 180 (65%) had secondary infections, and 148 (52%) died within 90 days. Patients in the VIR-N1-Zero group had the least severe disease: 81 (54%) of 150 received IMV, 34 (23%) developed acute kidney injury, 47 (32%) had secondary infections, and 26 (17%) died within 90 days (OR for death 0·30, 95% CI 0·16-0·55; p<0·0001, compared with the VIR-N1-Storm group). 106 (26%) of 403 patients in the VIR-N1-Low group died within 90 days (OR for death 0·39, 95% CI 0·26-0·57; p<0·0001, compared with the VIR-N1-Storm group). Interpretation: The presence of a so-called viral storm is associated with increased all-cause death in patients admitted to the intensive care unit with severe COVID-19. Preventing this viral storm could help to reduce poor outcomes. Viral storm could be an enrichment marker for treatment with antivirals or purification devices to remove viral components from the blood. | es_ES |
dc.description.sponsorship | This work was supported by grants from the Instituto de Salud Carlos III (FONDO-COVID19, COV20/00110, CIBERES, 06/06/0028; AT), Proyectos de Investigación en Salud (PI19/00590; JFB-M), Miguel Servet (CP20/00041; DdG-C), Sara Borrell (CD018/0123; APT), and Predoctorales de Formación en Investigación en Salud (FI20/00278; AdF). We also received funds from Programa de Donaciones Estar Preparados, UNESPA (Madrid, Spain), and from the Canadian Institutes of Health Research (CIHR OV2–170357; DJK and JFB-M), Research Nova Scotia, Li-Ka Shing Foundation (DJK), and finally by a Research Grant 2020 from ESCMID (APT). COV20/00110, PI19/00590, CP20/00041, CD018/0123, FI20/00278 were co-funded by European Regional Development Fund and European Social Fund (A way to make Europe, and Investing in your future). We thank the IRB-Lleida Biobank 119 (B.0000682) and Plataforma Biobancos PT17/0015/0027 in Lleida, the Hospital Clinic Barcelona (HCB)-IDIBAPS biobank in Barcelona, and the National DNA Bank and the Hospital Universitario de Salamanca biobank (both in Salamanca) for their logistical support with sample processing and storage. We are indebted to the Fundació Glòria Soler for its contribution and support to the COVIDBANK of HCBIDIBAPS Biobank. This work was not supported by any pharmaceutical company or other agency. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Elsevier | es_ES |
dc.type.hasVersion | VoR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | COVID-19 | es_ES |
dc.subject | Spain | es_ES |
dc.title | Effect of viral storm in patients admitted to intensive care units with severe COVID-19 in Spain: a multicentre, prospective, cohort study | es_ES |
dc.type | journal article | es_ES |
dc.rights.license | Atribución 4.0 Internacional | * |
dc.identifier.pubmedID | 37116517 | es_ES |
dc.format.volume | 4 | |
dc.format.number | 6 | es_ES |
dc.format.page | e431-e441 | |
dc.identifier.doi | 10.1016/S2666-5247(23)00041-1 | es_ES |
dc.contributor.funder | Instituto de Salud Carlos III | es_ES |
dc.contributor.funder | Canadian Institutes of Health Research | es_ES |
dc.contributor.funder | Li Ka Shing Foundation | es_ES |
dc.contributor.funder | European Society of Clinical Microbiology and Infectious Diseases | es_ES |
dc.contributor.funder | Centro de Investigación Biomédica en Red - CIBERES (Enfermedades Respiratorias) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) | es_ES |
dc.contributor.funder | Unión Europea. Fondo Social Europeo (ESF/FSE) | es_ES |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 2666-5247 | es_ES |
dc.relation.publisherversion | https://doi.org/10.1016/S2666-5247(23)00041-1 | es_ES |
dc.identifier.journal | The Lancet. Microbe | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.rights.accessRights | open access | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/COV20/00110 | es_ES |
dc.relation.projectFIS | info:fis/Instituto de Salud Carlos III/Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I/Subprograma Estatal de Generación de Conocimiento/PI19 - Proyectos de investigacion en salud (AES 2019). Modalidad proyectos en salud. (2019)/PI19/00590 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CP20/00041 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/CD018/0123 | es_ES |
dc.relation.projectFIS | info:eu-repo/grantAgreement/ES/FI20/00278 | es_ES |